Redx Pharma
New funds provide runway through 2024 catalystsRedx Pharma
Two key Phase II results on track for next 12 monthsRedx Pharma
ROCK solid start in cancer-associated fibrosisRedx Pharma
Fundamentals intact with catalysts on the horizonRedx Pharma
‘004 mono insufficient in BTC; H223 combo is keyRedx Pharma
Recommended all share combination with JounceRedx Pharma
RXC007 recruitment scales up; data now Q124Redx Pharma
Key Phase II data for lead assets expected during H223Redx Pharma
Laying the foundations for further delivery in 2023Redx Pharma
New data draws attention to promising fibrosis assets